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The growth and progression of solid tumors involves dynamic cross-talk between cancer epithelium and the surrounding
microenvironment. To date, molecular profiling has largely been restricted to the epithelial component of tumors; there-
fore, features underpinning the persistent protumorigenic phenotype of the tumor microenvironment are unknown. Using
whole-genome bisulfite sequencing, we show for the first time that cancer-associated fibroblasts (CAFs) from localized pros-
tate cancer display remarkably distinct and enduring genome-wide changes in DNAmethylation, significantly at enhancers
and promoters, compared to nonmalignant prostate fibroblasts (NPFs). Differentially methylated regions associated with
changes in gene expression have cancer-related functions and accurately distinguish CAFs fromNPFs. Remarkably, a subset
of changes is shared with prostate cancer epithelial cells, revealing the new concept of tumor-specific epigenome modifica-
tions in the tumor and its microenvironment. The distinct methylome of CAFs provides a novel epigenetic hallmark of the
cancer microenvironment and promises new biomarkers to improve interpretation of diagnostic samples.
[Supplemental material is available for this article.]
Most studies of the genome and epigenome landscape of tumors
focus on the aberrations in epithelial cancer cells. However, solid
tumors are embedded in an interactive and heterogenous cellular
microenvironment (Hanahan and Weinberg 2011), which in-
cludes a predominant population of cancer-associated fibroblasts
(CAFs) that can also display cellular heterogeneity (Franco et al.
2011; Kiskowski et al. 2011). Early pathology studies (Seemayer
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et al. 1979) and subsequent functional experiments (Olumi et al.
1999; Bhowmick et al. 2004) identified that prostatic CAFs pro-
mote tumor development and progression. CAFs also enhance
the migration and proliferation of prostate cancer cells in vitro
(Ao et al. 2007; Paland et al. 2009; Clark et al. 2013). The differenc-
es between CAFs and NPFs are known to be permanent, as CAFs re-
tain their protumorigenic phenotype and characteristic gene
expression signature in primary cell culturewithout epithelial cells
(Zhao et al. 2007).
It remains unknown how these enduring phenotypic chang-
es in CAFs are encoded at the molecular level. Initial studies sug-
gested that CAFs acquire genetic aberrations, but no recurrent
genome alterations were identified in subsequent reports (Qiu
et al. 2008; Ashida et al. 2012; Bianchi-Frias et al. 2016). Here we
ask if genome-wide differences in the epigenome underpin the
persistent phenotypic differences between CAFs and NPFs.
Earlier studies using low-resolution techniques found examples
of DNA methylation changes in CAFs or tumor stroma from vari-
ous cancer types (Hu et al. 2005; Fiegl et al. 2006; Hanson et al.
2006; Rodriguez-Canales et al. 2007; Dawsey et al. 2008; Jiang
et al. 2008; Banerjee et al. 2014; Vizoso et al. 2015). However,
the full epigenome landscape of CAFs remains uncharted, so the
precise epigenetic changes and their contribution to altered tran-
scriptional patterns is unknown.
To explore the epigenetic and functional alterations that
define CAFs, we used whole-genome bisulfite sequencing
(WGBS) to profile the DNA methylome of CAFs and matched
NPFs from patients with localized prostate cancer. In parallel, we
used single-nucleotide polymorphism (SNP) arrays to assess geno-
mic integrity, RNA-seq to measure mRNA abundance, and DNA
methylation arrays and targeted bisulfite sequencing to determine
the technical and biological reproducibility of changes in DNA
methylation between patients.
Results
CAFs from a spectrum of localized prostate cancers
are protumorigenic
To investigate functional and molecular changes that arise in the
prostate cancer microenvironment of different patients, we used
primary cells from 17 men undergoing a radical prostatectomy.
The cohort is typical of the diverse spectrum of localized sporadic
prostate cancers treated with curative intent, including moderate-
to high-grade disease (Supplemental Table S1). To isolate and
purify CAFs and NPFs, we first established primary cultures, which
are likely heterogeneous populations of fibroblast subgroups,
from digested tumor tissue and matched nonmalignant tissue
(Fig. 1A; Supplemental Table S1). All patient specimens were care-
fully validated using pathology (Fig. 1B), and cultures of CAFs
and NPFs were shown to have typical fibroblast morphology and
expressed stromal (vimentin), but not epithelial markers (cytoker-
atin 8/18, high molecular weight cytokeratin) (Supplemental
Table S1).
Next, we verified the phenotypic and functional differences
between patient-matched sets of fibroblasts. CAFs and NPFs differ-
entially expressed several markers previously used to differentiate
between CAFs and NPFs, including SFPR1 (Supplemental Fig.
S1A; Supplemental Table S1; Joesting et al. 2005; Franco et al.
2011; Kiskowski et al. 2011; Orr et al. 2012). We found that CAFs
were protumorigenic in classical in vivo tissue recombination as-
says (Fig. 1C; Supplemental Table S1) and in a novel in vitro cocul-
ture assay (Supplemental Table S1; Clark et al. 2013). Collectively,
these data confirmed that the primary cells exhibit the defining
functional features of CAFs and NPFs, making this one of the larg-
est and most rigorously profiled cohorts of patient-matched fibro-






Figure 1. Isolation and validation of matched CAFs and NPFs from pa-
tient tissue. Representative data from patient 1. (A) Matched nonmalig-
nant (blue) and cancer (red) tissue were dissected from the same radical
prostatectomy specimen and used to establish primary cultures of CAFs
and NPFs. (Scale) 2 cm. (B) Hematoxylin and eosin staining confirmed
that NPFs were from a nonmalignant region and that CAFs were from a re-
gion of Gleason 3+4 cancer. (Scales) 500 µm. (C) Grafts from tissue recom-
bination assays with BPH-1 epithelial cells stained for SV40 T antigen
(brown) and nuclei counterstained with hematoxylin (blue). BPH-1 cells
combined with NPFs formed well-differentiated structures, evident from
organized layers of epithelial cells with abundant keratinization (arrows).
In contrast, BPH-1 cells combined with CAFs formed poorly differentiated
structures, consistent with tumorigenesis, apparent from the disorganized
clusters of epithelial cells and limited keratinization. White boxes indicate
the areas shown in higher magnification. (Scales) 500 µm for low magni-
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Prostate cancer fibroblasts show discrete changes in DNA
methylation but no genetic copy number changes
To determine if there were genetic copy number alterations, we as-
sayed the low passage (P2–6) patient-matched fibroblasts (patients
1–4) on the Illumina Infinium Omni2.5-8 BeadChip genotyping
platformand foundno evidence of large-scale genomic aberrations
within any NPF–CAF patient pair (Fig. 2A; Supplemental Fig. S1B).
Next,weusedWGBS to comprehensively analyze theDNAmethyl-
ation profiles of the same samples. We obtained >7× coverage for
each sample and efficient bisulfite conversion (98.5%–99.7%).
For cross-platform validation, genome-widemethylationwasmea-
sured using the Illumina Infinium HumanMethylation450
BeadChip (450K) and showed excellent agreement between repli-
cates (Pearson’s r = 0.88–0.90, P < 2.2 × 10−16) (Supplemental Fig.
S1C).Overall,we found that thegenome-widemethylationprofiles
were highly correlated between NPFs and CAFs (Pearson’s r = 0.90,
P < 2.2 × 10−16) (Fig. 2B), particularly compared to other related cell
types (Supplemental Fig. S1D). Both CAFs and NPFs displayed typ-




Figure 2. CAFs and NPFs have similar global methylation profiles but discrete methylomic differences. (A) Representative SNP array data (patient 1)
showing no large-scale genomic aberrations. (B) High correlation (r = 0.90, P < 2.2 × 10−16) of WGBS DNA methylation levels between CAFs and NPFs
(n = 4 pairs) indicates no global perturbations between cell types. (C ) MDS plot of the 10% most variably methylated regions shows clear separation of
CAFs and NPFs. (D) The number of hypermethylated (green) and hypomethylated (purple) DMRs in CAFs according to the percentage change in DNA
methylation. (E) WBGS and 450K data for PITX2 for each NPF (blue) and CAF (red). The average difference in DNA methylation in CAFs compared to
NPFs is shown in purple. The height of each vertical line represents the percentage of DNA methylation at each CpG site. The locations of 450K probes
are shown in gray. The purple box highlights a large region of hypomethylation measured on both platforms.
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overall levels of methylation across CpG islands, shores, and non-
CpG islands (Supplemental Fig. S1E). Notably, we found no evi-
denceof theglobalhypomethylation that typicallyoccurs in tumor
epithelial cells (Supplemental Fig. S1E,F) andas previously reported
for CAFs from gastric and non-small cell lung cancers (Jiang et al.
2008; Vizoso et al. 2015).
Despite the lack of global differences in methylation between
CAFs andNPFs,multidimensional scaling analysis of themost var-
iably methylated CpG sites showed clear separation by cell type,
indicating regions of differential methylation between CAFs and
NPFs (Fig. 2C). Using bsseq analysis (Hansen et al. 2012), we iden-
tified 7534 distinct differentially methylated regions (DMRs) be-
tween patient-matched CAFs and NPFs (absolute methylation
difference >10%, with a minimum of three CpGs sites per region)
(Supplemental Table S2). We defined hypomethylated and hyper-
methylated DMRs as discrete regions with, respectively, decreased
or increased methylation in CAFs compared to NPFs. We found
that CAFs have more hypomethylated DMRs (n = 5038, 2.2 Mb
of the genome) compared to hypermethylated DMRs (n = 2496;
1.1 Mb of the genome) (Fig. 2D), although hypomethylated
DMRs tend to be slightly smaller (460 vs. 428 bp; Mann-
Whitney U test P = 4.8 × 10−7) (Supplemental Fig. S2A). When we
grouped DMRs by the level of methylation difference (Fig. 2D),
we observed that regions with greater differences are significantly
larger in size (Spearman’s correlation hypermethylated ρ = 0.37,
P < 2.2 × 10−16, and hypomethylated ρ =−0.35, P < 2.2 × 10−16)
(Supplemental Fig. S2B). Notably, the regions with the greatest
methylation differences also occur at sites with either low (hyper)
or high (hypo) methylation in NPFs (Supplemental Fig. S2C). We
also found significant cross-platform validation of DMRs for
each patient (Supplemental Fig. S2D,E). For example, an ∼400-kb
region spanning the gene body of PITX2 showed extensive hypo-
methylation in all fourCAFs compared to patient-matchedNPFs in
both WGBS and 450K data sets (Fig. 2E).
Differential methylation in CAFs occurs at regulatory regions
To examine the potential functional importance of DMRs in CAFs,
we determined their location relative to different genomic features
(Fig. 3A,B). We found that most DMRs are outside CpG islands, al-
though the proportion of DMRs overlapping CpG islands does in-
crease with the degree of methylation change between CAFs and
NPFs (Fig. 3B). Relative to annotated protein-coding genes, 45% of
hypermethylated and 39% of hypomethylated DMRs are in gene
bodies (Fig. 3B). Hypomethylated DMRs are more common in
gene promoters (33% hypomethylated vs. 21% hypermethylated)
and are located closer to transcription start sites (TSSs) compared
to hypermethylated DMRs (median distance to TSS hypomethy-
lated DMRs = 9343 bp vs. hypermethylated DMRs = 15,726 bp,
Mann-Whitney U test, P = 2.6 × 10−18) (Supplemental Fig. S2F).
To further examine the association between DMRs and regu-
latory elements, we measured their overlap using published
ChromHMMsegmentation from fibroblasts, downloaded through
UCSC Genome Browser (Ernst et al. 2011). Hypermethylated and
hypomethylated DMRs are both enriched for regulatory elements,
including strong enhancers and active promoters (Fig. 3C). This
enrichment increases in DMRs with larger differences in methyla-
tion, suggesting functional relevance (Supplemental Fig. S2G,H).
To confirm the association betweenDMRs and active regulatory re-
gions, we partitioned methylomes into CpG-poor lowmethylated
regions (LMRs) andCpG-rich, fully unmethylated regions (UMRs),
which correspond to proximal (promoter) and distal regulatory
(enhancer) sites (Supplemental Fig. S3A–E; Stadler et al. 2011;
Burger et al. 2013). Notably, 39% of hypermethylated DMRs and
42% of hypomethylated DMRs were located within LMRs and
UMRs that are specific to either NPFs or CAFs, respectively (Fig.
3D). For example, the hypomethylated DMR in the gene body of
CD9 occurs at a CAF-specific LMR and aligns with a regionmarked
by the active histone modification H3K27ac (Fig. 3E). We also ob-
served that an additional ∼30% of DMRs in CAFs extended from
LMRs or UMRs preexisting in NPFs (Fig. 3D). For example, the
hypomethylatedDMR in IGFBP2 arises froma sharedUMR that ex-
tends an additional ∼1800 bp in CAFs (Fig. 3F). Collectively, these
analyses show that methylation differences identified in CAFs are
significantly enriched at unique regulatory regions.
Differentially methylated regions in CAFs associate with
functional changes
Given that DMRs lie in regulatory regions, we next investigated
whether they are associated with genes in biologically relevant
pathways using the Genomic Regions Enrichment of Annotations
Tool (GREAT) (Fig. 4A,B; McLean et al. 2010). Among DMRs
with at least 30% difference inmethylation levels, we observed en-
richment of terms related to developmental processes and tran-
scription factor binding, predominantly comprising genes from
the T-box (TBX), forkhead box (FOX), and homeobox (HOX)
gene families. We also observed enrichment of terms related to li-
gand-activated cell signaling, including the TGFbeta pathway and
estrogen receptor (ERα) signaling.
To further assess the functional significance of the DMRs, we
used stranded RNA-seq to determine whether the nearest protein-
coding gene to each DMR was differentially expressed between
CAFs and NPFs. We identified 445 DMRs associated with 220 dif-
ferentially expressed genes (P < 0.05, absolute fold change ≥1.5)
and termed these sites differentially expressed DMRs (DE-DMRs)
(Supplemental Table S3).We confirmed gene expression differenc-
es in cross-platform validation with Affymetrix Human Gene
1.0ST Arrays (Supplemental Fig. S4A). The 162 DE-DMR genes
that are more highly expressed in CAFs are predominantly associ-
ated with hypomethylated DMRs (278 hypomethylated vs. 74
hypermethylated), whereas the 58 DE-DMR genes with decreased
expression in CAFs are more commonly associated with hyperme-
thylated DMRs (36 hypomethylated vs. 57 hypermethylated) (Fig.
5A). Compared with the full set of DMRs, DE-DMRs have signifi-
cantly greater difference in methylation between CAFs and NPFs
(permutation test, P = 1 × 10−4 hypermethylated, and P = 1.05 ×
10−2 hypomethylated), but no difference in CpG density or genic
distribution (Supplemental Table S4).
GREAT analysis of the DE-DMRs also revealed strong enrich-
ment for developmental processes and genes associatedwith extra-
cellularmatrix (Supplemental Fig. S5A). A complementary analysis
using Ingenuity Pathway Analysis (IPA) identified seven networks
for the hypermethylated DE-DMRs and 14 networks for the hypo-
methylated DE-DMRs (Supplemental Table S5) with enrichment
for diseases and biological functions, including cancer and organ-
ismal development (Supplemental Fig. S5B). Predicted upstream
regulators of DE-DMR genes included members of the TGFbeta
family (Supplemental Table S5).
Functional DMRs define cell-type specificity between CAFs
and NPFs across independent patients
We evaluated the cell-type specificity of DE-DMRs in CAFs and










Figure 3. DMRs occur at regulatory regions. (A) Schematic showing the genomic regions investigated in B. (B) The distribution of all CAF–NPFDMRs, and
CAF–NPF DMRs grouped by percentage change in methylation, relative to each type of genomic region in A. (C) Comparison of CAF DMRs with
ChromHMM data from normal fibroblasts. Numbers denote the number of DMRs associated with each type of region. Note that ENCODE defines two
types of strong enhancers, weak enhancers, and repetitive/CNV regions. (D) The proportions of DMRs associated with LMRs and UMRs that are unique
to NPFs (for hypermethylated DMRs) or CAFs (for hypomethylated DMRs) or that extend from LMRs and UMRs that are shared by NPFs and CAFs.
(E) Pooled WGBS data (n = 4 patients) showing a hypomethylated DMR in the CD9 gene (blue box) occurring at a regulatory region defined
by ChromHMM H3K27ac peaks (pink track) and a unique CAF LMR. Shared UMRs and LMRs between CAFs and NPFs are also shown (orange boxes).
(F) A hypomethylated DMR in IGFBP2 (blue box) arising from a shared UMR that extends in CAFs. The DMR lies in a regulatory region defined
by ChromHMM H3K27ac peaks.
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Figure 4. DMRs are associated with genes in cancer-related pathways. Genomic regions enrichment (GREAT) analysis of hypermethylated (A) and hypo-
methylated (B) DMRs in CAFs compared to NPFs. Bar charts display −log10 P-values from the binomial test for selected categories. Analysis shows enrich-
ment for developmental processes and transcription factor binding (orange) and ligand-activated cell signaling (blue). Word clouds show the genes











Figure 5. Consistent changes in DMRs associated with differentially expressed genes (DE-DMRs) between patients. (A) Scatter plot of DE-DMRs showing
the average percentage difference in DNAmethylation versus average log fold change (logFC) in expression (n = 4 CAF-NPF pairs). Dotted lines indicate the
thresholds forDE-DMRs. (B) Nonhierarchical clustering of CAFs andNPFs from10 independent patients based on themethylation status of 14 candidateDE-
DMRs. The heatmap shows the percentage of DNAmethylation of each DE-DMR in each sample. (C ) Receiver operating characteristic (ROC) curve analysis
based on the DNA methylation status of the 14 candidate DE-DMRs (AUC = 0.98, n = 10 CAF-NPF pairs). Representative examples of DE-DMRs in the EBF1
(D), EPHB6 (E), andHOXD8 (F) genes ([blue] NPF; [red] CAF), showing the averagemethylation across the amplicon in CAFs versusNPFs (one-sided paired t-
test), the percentage of DNA methylation at each CpG site in each sample (trendlines denote the mean), ROC curves, the relative gene expression in each
sample (with mean ± SEM, one-sided t-test), and the significant correlation between methylation and expression (Spearman’s test). The # symbol denotes
that HOXD8 expression was below the detection limit for NPF10, NPF13, NPF15, and NPF17; therefore, n = 6 for NPFs and n = 10 for CAFs.
Epigenetics of the cancer microenvironment
Genome Research 631
www.genome.org
 Cold Spring Harbor Laboratory Press on May 20, 2018 - Published by genome.cshlp.orgDownloaded from 
performed genome-wide comparisons with three additional pa-
tients using 450K methylation BeadChips and gene expression ar-
rays. Of the DE-DMRs covered by the 450K arrays, 90% of probes
(120/145) validated the WGBS data (Supplemental Fig. S4B).
Similarly, a high proportion (72%; 150/209) of the DE-DMR genes
targeted by the expression array were consistent with the RNA-seq
data (Supplemental Fig. S4C). Moreover we observed a strong
correlation in the average CAF–NPF methylation and expression
differences between the original and additional patients (DNA
methylation r = 0.84, P < 2.2 × 10−16; gene expression: r = 0.53,
P < 2.2 × 10−16) (Supplemental Fig. S4D,E).
Our second approach to validate DE-DMRs was to examine
candidate genes using targeted bisulfite sequencing and quanti-
tative RT-PCR for 10 new, extensively validated, patient-
matched pairs of CAFs and NPFs. We selected 14 candidate
genes with coordinated changes in methylation and expres-
sion and known roles in prostate cancer and/or the tumor
microenvironment (summarized in Supplemental Table S6). All
candidate regions showed a significant change in methylation
(P < 0.05) in agreement with the WGBS data (Fig. 5B–F;
Supplemental Fig. S6A,B; Supplemental Table S7). Notably, non-
hierarchical clustering and ROC analysis based on these loci
both correctly distinguished between CAFs and NPFs (19/20 fi-
broblast cultures, AUC 0.98) (Fig. 5B,C). Methylation levels at
individual DMRs also discriminated between CAFs and NPFs, in-
cluding HOXD8 with AUC = 1 (Fig. 5D–F; Supplemental Fig.
S6C; Supplemental Table S7). We also found that 13 of 14 can-
didate genes were significantly differentially expressed in CAFs
versus NPFs (P < 0.05) (Fig. 5D–F; Supplemental Fig. S6D).
There was a strong negative correlation between expression
and methylation for IGFBP2, ITGA11, ESR1, and EPHB6, all of
which have DMRs downstream from their promoter. In contrast,
there were strong positive correlations for PITX2, with a DMR in
the last intron, and HOXD8 and EBF1, which have intergenic
DMRs, suggesting a mechanistic link between methylation and
expression at these loci (Fig. 5D–F; Supplemental Fig. S6E).
Collectively, our genome-wide and targeted validation, in inde-
pendent patients, demonstrate that DE-DMRs are highly consis-
tent between patients and define cell-type specificity between
CAFs and NPFs.
Diagnostic and prognostic value of tumor-specific DMRs
We next asked whether the DMRs in CAFs are shared by epithelial
prostate cancer cells. For this we used WGBS data from LNCaP
prostate cancer epithelial cells and PrEC normal prostate epithelial
cells (Fig. 6A) to identify CAF–NPF DMRs that showed a mean
DNA methylation difference >30% in LNCaP compared to PrEC.
This revealed that 10% of CAF-NPF DMRs showed robust DNA
methylation alterations in LNCaP versus PrEC cells (n = 493/
5038 hypomethylated, n = 294/2496, hypermethylated) (Fig. 6B;
Supplemental Table S8). We defined these regions as tumor-spe-
cific DMRs (tsDMRs). GREAT analysis showed that the tsDMRs
were significantly enriched in biological processes associated
with development (with genes including T-box and HOX genes)
and endocrine hormone secretion (Supplemental Fig. S7A,B).
Furthermore, Ingenuity Pathway Analysis showed that the
tsDMRs were overrepresented in genes associated with cancer
and reproductive system disease, and analysis of the upstream reg-
ulators of these genes predicted regulation by the estrogen recep-
tor and members of the TGFbeta pathway (Supplemental Fig. S7C;
Supplemental Table S5).
Second, to explore the potential clinical relevance of tsDMRs,
we investigated methylation profiles of clinical prostate cancer
specimens, which contain a heterogeneous mix of epithelium
and stroma, a confounding feature for many diagnostic signatures
(Isella et al. 2015). We used publicly available 450K methylation
data of tumor and normal prostate specimens from The Cancer
Genome Atlas (TCGA) (The Cancer Genome Atlas Research
Network 2015). Of the subset of tsDMRs covered by 450K probes,
83% (91/109) of hypermethylated tsDMRs and 65% (60/92)
of hypomethylated tsDMRs showed consistentmethylation differ-
ences (FDR < 0.05) in the TCGA samples (Fig. 6A,B; Supplemental
Table S9). Furthermore, ROCanalysis showed that 50 hypermethy-
lated tsDMRs and 15 hypomethylated tsDMRs accurately discrim-
inated between the tumor and normal samples with AUC> 0.8
(Supplemental Table S9; Supplemental Fig. S8).
Some of the most striking tsDMRs flank the TBX3 gene en-
coding a developmental transcriptional repressor. We found con-
cordant hypermethylated DMRs in CAFs and LNCaP cells that
truncate a UMR covering TBX3 (Fig. 7A). Importantly, WBGS
data from four clinical samples confirmed that the tsDMRs are con-
sistently hypermethylated in tumors compared to matched non-
malignant prostate tissue, as did 450K data from TCGA (Fig. 7B).
Collectively, the TBX3 tsDMRs discriminated between normal
and cancer samples in TCGA with an AUC of 0.84 (Fig. 7C); how-
ever, individual tsDMRs had AUCs of up to 0.92 (Supplemental
Table S9). Other notable tsDMRs exist in regulatory enhancer re-
gions of the ETS Homologous Factor (EHF), Mutated in Colorectal
Cancer (MCC), and STEAP2 (Prostate Cancer Associated Protein 1)
genes (Supplemental Fig. S8). These tsDMRs all had consistent
changes in DNA methylation across WGBS data from CAFs,
LNCaP cells, and tumor tissue, and 450K data from TCGA.
Unlike previous studies of prostate CAFs and tumor stroma
(Hanson et al. 2006; Rodriguez-Canales et al. 2007; Banerjee
et al. 2014), the GSTP1 CpG island promoter was only hyper-
methylated in prostate cancer epithelial cells and not in CAFs
(Fig. 7D).
The abundance of reactive stroma in prostate cancer has pre-
viously been linked to recurrence-free survival (Ayala et al. 2003),
so we explored the possible association of tsDMRs with patient
prognosis. We used two publicly available gene expression data
sets (Glinsky et al. 2004; Taylor et al. 2010), as comparable cohorts
withmethylation data and extensive clinical follow-up arenot cur-
rently available. We identified tsDMRs associated with gene
expression changes and examined their relationship with recur-
rence-free survival (Supplemental Methods). We identified an
intronic hypermethylated tsDMR in the CCDC68 gene, which
was also consistently down-regulated in CAFs, LNCaPs, and
TCGA tumor samples (Fig. 8A–C). CCDC68was recently identified
as a tumor suppressor gene in pancreatic cancer and functional
studies showed that decreased CCDC68 expression increases tu-
mor growth (Radulovich et al. 2015). Since DNA methylation of
TSS probes surrounding the tsDMR and transcript abundance of
CCDC68 are highly correlated (Fig. 8D), we used CCDC68 expres-
sion as a surrogate for the tsDMR in Kaplan–Meier analysis. In
agreement with the decreased expression and hypermethylation
of CCDC68 in CAFs and LNCaP cells, patients with lower
CCDC68 gene expression showed significantly decreased recur-
rence-free survival compared to patients with high CCDC68 ex-
pression (log-rank test, P = 0.012, hazard ratio (HR) = 2.798, 95%
confidence interval (CI) = 1.252–6.251) (Fig. 8E), suggesting that
some tsDMRs may also be associated with patient prognosis. We
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Figure 6. Tumor-specific DMRs common to CAFs and cancer cells. (A) Circos plot showing commonDMRs identified byWGBS of CAF versus NPF, WGBS
of LNCaP versus PrEC cells (middle), and 450K arrays of cancer versus normal tissue fromTCGA (inner). (Green) Hypermethylated; (purple) hypomethylated.
The height of each track represents a 50% methylation difference. Note that only tsDMRs are shown for LNCaP:PrEC and TCGA samples. (B) Pie charts
showing the proportion of DMRs that are tsDMRs and that are consistent with 450K data from TCGA.
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Figure 7. Diagnostic value of tumor-specific DMRs. (A) WGBS data for TBX3 in fibroblasts (CAFs vs. NPFs, n = 4 pairs), epithelial cells (LNCaP vs. PrEC),
and patient tissue (matched tumor vs. normal) showing consistent hypermethylated tsDMRs in each data set. (B) 450K data from TCGA is also shown with
dots indicating the DNAmethylation status of tumor (red, n = 392) and normal (blue, n = 45) samples at each probe (trendlines denotemeanmethylation).
(C ) An ROC curve showing that the average methylation status of the four TBX3 tsDMRs discriminates between normal and cancer tissues in TCGA. (D)
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from an additional cohort (log-rank test, P = 0.02, HR = 2.295, 95%
CI = 1.158–4.55) (Fig. 8F; Glinsky et al. 2004).
Discussion
Genomic and epigenetic aberrations in tumor epithelia arewell de-
scribed, but the molecular changes in the surrounding microenvi-
ronment, predominated by CAFs, are controversial (Campbell
et al. 2009). Here, we generated high-resolution methylome
maps of purified CAFs and matched NPFs. We found no evidence
of gross genomic alterations in CAFs, similar to other reports (Qiu
et al. 2008; Bianchi-Frias et al. 2016). Instead, CAFs harbor discrete
and consistent DNA methylation differences, predominantly at
regulatory regions across the genome. We identified a core set of
genes with coordinated changes in DNA methylation and mRNA
expression (DE-DMRs), including genes involved in tissue devel-
opment and stromal-epithelial cell signaling. These DE-DMRs dis-
tinguished between CAFs and NPFs with high sensitivity and
specificity across patients. Further, we identified common DMRs
in CAFs and prostate cancer cells with diagnostic potential.
Collectively our data demonstrate that the phenotype of CAFs is
not merely a transient reaction to adjacent cancer epithelium,
but involves enduring and recurrent epigenome changes.
Previous studies reported widespread hypomethylation in
CAFs, but with techniques that do not assess the entire genome
(Jiang et al. 2008; Vizoso et al. 2015). Using WGBS, we revealed
that CAFs have locus-specific changes in DNA methylation rather
than the global loss of DNAmethylation that commonly occurs in
cancer epithelial cells. We detected more hypomethylated than
hypermethylated DMRs, but do not classify this as global hypome-
thylation since they span a small fraction of the genome. Notably,
we found thatmanyDMRs are at regulatory regions, including pro-
moters and enhancers, which are not interrogated by lower resolu-
tion methods. The presence of DMRs in promoters is consistent
with reported differences in transcription factor binding at tran-
scriptional start sites between prostate CAFs and NPFs (Leach
A
C D E F
B
Figure 8. CCDC68 has prognostic value in localized prostate cancer. (A) WGBS data showing consistent hypermethylation of CCDC68 in CAFs versus
NPFs (n = 4 pairs), LNCaP versus PrEC, and matched tumor versus normal tissues (n = 4 pairs). The locations of 450K probes are shown in gray. (B)
Scatter plot of differentially expressed genes associated with hypermethylated tsDMRs. CCDC68 (purple) is down-regulated in CAFs versus NPFs (n = 4
pairs) and also in LNCaP versus PrEC cells. (C ) Box plot showing decreased CCDC68 expression in tumor (n = 392) versus normal (n = 45) tissue samples
from TCGA. (D) The relationship between 450K methylation averaged across all probes at the TSS of CCDC68 and gene expression for TCGA tumor spec-
imens. (E,F) Kaplan–Meier curves showing low (blue) CCDC68 expression is associated with poor recurrence-free survival compared to high CCDC68 ex-
pression (orange) in Taylor (E) and Glinsky (F ) data sets (n = 127 and n = 79 respectively, log-rank test).
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et al. 2017; Nash et al. 2017). Many of the CAF-associated DMRs
also create ectopic enhancer (LMRs) and promoter (UMRs) ele-
ments, and more than a third extend preexisting LMRs or UMRs,
indicating a cancer-associated spread of hyper- or hypomethyla-
tion at the border of these regulatory elements. However, further
analysis is required to address if there are resulting alterations in
enhancer–promoter chromatin interactions.
DMRs are extremely consistent in CAFs, with high concor-
dance across different experimental platforms and independent
patient samples. This is remarkable given that the CAFs were de-
rived frompatients with a range of clinical features and the consid-
erable inter-patient tumor and stoma heterogeneity reported in
localized sporadic prostate cancer (Franco et al. 2011; Kiskowski
et al. 2011; The Cancer Genome Atlas Research Network 2015).
One of the challenges in the field is to validate CAFs without using
laborious functional assays. However, we found that a core set of
DMRs could distinguish between CAFs and NPFs with high sensi-
tivity and specificity, providing the first epigenetic signature for
these two cell types. This signature may also provide a way to esti-
mate the proportion of CAFs in patient tissue in future studies.
Strikingly, a subset of DMRs in CAFs is also shared with DMRs
identified in prostate cancer epithelial cells. These newly defined
tumor-specific (ts) DMRs were consistent between different pa-
tients and accurately distinguished normal from tumor tissue.
The tsDMRs transcend the considerable global differences in
DNAmethylation between each cell type, since, unlike CAFs, can-
cer cells undergo extensive hypomethylation (Hansen et al. 2011;
Berman et al. 2012; Kretzmer et al. 2015). Notably, the tsDMRs are
strongly overrepresented in developmental gene families and
genes involved in endocrine hormone secretion, such as TBX3
(Holterhus et al. 2007; Beukers et al. 2015), suggesting that they
are associated with functional roles in cancer progression. Indeed
specific tsDMRs were found in known tumor suppressor genes
(for example, EHF [Albino et al. 2012] and MCC [Kohonen-
Corish et al. 2007]) and oncogenes (for example, STEAP2
[Whiteland et al. 2014]). Collectively, the tsDMRs suggest a con-
vergent malignant epigenetic pathway across cell types. We pro-
pose that tsDMRs may be used as tumor microenvironment-
based biomarkers for detecting prostate cancer in heterogeneous
clinical samples and biopsies that contain a mix of epithelium
and stroma. In summary, our study has wide ramifications for can-
cer diagnosis, as it highlights that it is not only the cancer epige-
nome that is remodeled, but that CAFs are also epigenetically
altered, giving rise to a new epigenetic hallmark of the cancer mi-
croenvironment that promises to have clinical utility.
Methods
Patient tissue
Primary fibroblasts (n = 17) were isolated from radical prostatecto-
my (RP) specimens collected with human ethics approval from
Monash University (2004/145), Cabrini Hospital (03-14-04-08),
and Epworth Hospital (53611). For WGBS, biopsies were taken
from four patients’RP tissue, retrievedwith humanethics approval
from the Garvan Institute/St Vincent’s Prostate Cancer biobank
(SVH File Number 12/231). See Supplemental Methods for more
details.
Cell culture and validation of prostatic fibroblasts
Primary cultures of NPFs and CAFs from matched nonmalignant
and cancer regions of RP tissue, respectively, were established and
validated as previously described (Clark et al. 2013; Lawrence
et al. 2013; Niranjan et al. 2013). See Supplemental Methods for
more details.
Whole-genome bisulfite sequencing
Library preparation of matched CAF–NPF samples (n = 4 pairs) and
LNCaP and PrEC cell lines was performed using the Illumina
Paired-end DNA Sample Prep Kit (Illumina) and sequencing per-
formed on the Illumina HiSeq 2500 platform. FFPE tumor and
matched adjacent normal tissue (n = 4 pairs) WGBS libraries were
prepared using the EpiGnome Methyl-Seq kit (Epicentre). See
Supplemental Methods for more details about library preparation
and data processing.
WGBS statistical analysis
The R package bsseq (Hansen et al. 2012) was used to identify
CAF–NPF DMRs. UMRs and LMRs were identified using the
MethylSeekR Bioconductor package (Burger et al. 2013). See
Supplemental Methods for more details.
Enrichment analysis for chromatin states
A BED-formatted annotation file of chromatin states for a normal
fibroblast cell line was downloaded through UCSC Genome
Browser (Ernst et al. 2011). The Genomic Association Tester
(GAT) simulation framework was used to assess enrichment of
WGBS DMRs in each chromatin state (Heger et al. 2013). See
Supplemental Methods for more details.
Microarray genome-wide DNA methylation analysis
DNA from seven patient-matched CAF–NPF pairs was bisulfite
treated using the EZ-96 DNA methylation kit (Zymo Research).
DNA methylation was quantified using the Infinium
HumanMethylation450 (450K) BeadChip (Illumina) run on the
HiScan System (Illumina). QC and processing were performed us-
ing the minfi package in R v1.12.0 (Aryee et al. 2014). See
Supplemental Methods for more details.
TCGA microarray genome-wide DNA methylation
Raw IDAT files and corresponding clinical and specimen data for
prostate adenocarcinoma samples were downloaded from https://
tcga-data.nci.nih.gov/tcgafiles on May 26, 2015 (TCGA data have
now been moved to https://portal.gdc.cancer.gov). We calculated
the mean methylation level for each tsDMR and then ascertained
the methylation difference between matched-tumor normal pairs
using paired t-tests. The receiver operating characteristic (ROC)
curve and area under the curve (AUC) were calculated using
ROCR v1.0-7 (Sing et al. 2005). See Supplemental Methods for
more details.
Bisulfite-amplicon sequencing with MiSeq
Independent verification analysis was performed on 10 additional
patient-matched CAF–NPF pairs. Bisulfite-PCR amplification was
performed using primers designed with Sequenom EpiDesigner
software (https://www.epidesigner.com) and conditions described
in Supplemental Table S10. Libraries were prepared using the
TruSeq DNA PCR-Free Low Sample Preparation Kit (Illumina).
See Supplemental Methods for more details about library prepara-
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RNA sequencing
CAF–NPF RNA (n = 4 pairs) was depleted of ribosomal RNA using
RiboZero (Illumina). Libraries were prepared using the TruSeq
Stranded Total RNA sample kit (Illumina), followed by directional
75-bp paired-end sequencing. See SupplementalMethods formore
details.We used in-house LNCaP and PrEC RNA-seq data (Taberlay
et al. 2016). All raw and processed data are publicly available at
https://www.ncbi.nlm.nih.gov/geo under accession number
GSE73784.
Microarray-based genome-wide expression analysis
CAF–NPF RNA (n = 7 pairs) was analyzed using the Human Gene
1.0 ST array (Affymetrix) in two sets. See Supplemental Methods
for more details.
Quantitative RT-PCR
Total RNA was reverse-transcribed using SuperScript III
(Invitrogen). All primers are listed in Supplemental Table S11. See
Supplemental Methods for more details.
Microarray-based genome-wide genotyping analysis
CAF–NPF DNA (n = 4 pairs) was used to assess genomic aberrations
using Infinium Omni2.5-8 BeadChips (Illumina). See Supplemen-
tal Methods for more details.
Gene ontology and pathway analysis
GREAT was used to analyze the functional significance of DMRs
(McLean et al. 2010). IPA software (IPA, QIAGEN) was used to
map lists of identified genes to their corresponding gene object
in the Ingenuity Knowledge Base. See Supplemental Methods for
more details.
Prognostic analysis
Prognostic analysis was undertaken using TCGA PRAD processed
RNA-seq V2 data, downloaded from https://tcga-data.nci.nih.
gov/tcgafiles on April 19, 2016 (TCGA data have now beenmoved
to https://portal.gdc.cancer.gov); RNA-seq data from the NCBI
GEO database with accession GSE21032 (Taylor et al. 2010);
and Affymetrix Human Genome U95Av2 array data from the
ONCOMINE Database (Glinsky et al. 2004). See Supplemental
Methods for more details.
Data access
The data generated as part of this study have been submitted to
the NCBI Gene Expression Omnibus (GEO; https://www.ncbi.
nlm.nih.gov/geo) under accession number GSE86260.
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